Nothing Special   »   [go: up one dir, main page]

DE122011100040I1 - Zusammensetzung, verfahren und instrument zur potenzierung der antitumoraktivitat und zur behandlungvon tumoren. - Google Patents

Zusammensetzung, verfahren und instrument zur potenzierung der antitumoraktivitat und zur behandlungvon tumoren.

Info

Publication number
DE122011100040I1
DE122011100040I1 DE201112100040 DE122011100040C DE122011100040I1 DE 122011100040 I1 DE122011100040 I1 DE 122011100040I1 DE 201112100040 DE201112100040 DE 201112100040 DE 122011100040 C DE122011100040 C DE 122011100040C DE 122011100040 I1 DE122011100040 I1 DE 122011100040I1
Authority
DE
Germany
Prior art keywords
composition
antitumor activity
instrument
treating tumors
potentiating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
DE201112100040
Other languages
English (en)
Other versions
DE122011100040I2 (de
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Taiho Pharmaceutical Co Ltd
Original Assignee
Taiho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taiho Pharmaceutical Co Ltd filed Critical Taiho Pharmaceutical Co Ltd
Publication of DE122011100040I1 publication Critical patent/DE122011100040I1/de
Publication of DE122011100040I2 publication Critical patent/DE122011100040I2/de
Active legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DE201112100040 1991-05-27 1992-05-22 Zusammensetzung, verfahren und instrument zur potenzierung der antitumoraktivitat und zur behandlungvon tumoren. Active DE122011100040I2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP12124791 1991-05-27
PCT/JP1992/000656 WO1992021345A1 (fr) 1991-05-27 1992-05-22 Composition, methode et trousse pour le traitement des tumeurs par stimulation de l'activite antitumorale

Publications (2)

Publication Number Publication Date
DE122011100040I1 true DE122011100040I1 (de) 2011-11-24
DE122011100040I2 DE122011100040I2 (de) 2012-08-09

Family

ID=14806544

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69227571T Expired - Lifetime DE69227571T2 (de) 1991-05-27 1992-05-22 Zusammensetzung, verfahren und instrument zur potenzierung der antitumoraktivität und zur behandlung von tumoren
DE201112100040 Active DE122011100040I2 (de) 1991-05-27 1992-05-22 Zusammensetzung, verfahren und instrument zur potenzierung der antitumoraktivitat und zur behandlungvon tumoren.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE69227571T Expired - Lifetime DE69227571T2 (de) 1991-05-27 1992-05-22 Zusammensetzung, verfahren und instrument zur potenzierung der antitumoraktivität und zur behandlung von tumoren

Country Status (14)

Country Link
US (1) US5525603A (de)
EP (1) EP0543015B1 (de)
JP (1) JP2614164B2 (de)
KR (1) KR0148589B1 (de)
AT (1) ATE173165T1 (de)
AU (1) AU654555B2 (de)
CA (1) CA2087540C (de)
DE (2) DE69227571T2 (de)
DK (1) DK0543015T3 (de)
ES (1) ES2124257T4 (de)
HU (1) HU211987A9 (de)
LU (1) LU91852I2 (de)
TW (1) TW209833B (de)
WO (1) WO1992021345A1 (de)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5719132A (en) * 1996-06-27 1998-02-17 Bristol-Myers Squibb Company Compositions and methods of treating HIV with d4T, 5-fluorouracil/tegafur, and uracil
NZ330360A (en) * 1997-06-02 1999-03-29 Hoffmann La Roche 5'-deoxy-cytidine derivatives, their manufacture and use as antitumoral agents
JPH11116564A (ja) * 1997-10-09 1999-04-27 Otsuka Chem Co Ltd クロモン誘導体
US6005098A (en) * 1998-02-06 1999-12-21 Hoffmann-La Roche Inc. 5'deoxycytidine derivatives
US6538001B1 (en) * 1998-10-12 2003-03-25 Nikolai Borisovich Leonidov Crystalline modification of 5-fluoro-1-(tetrahydro-2-furyl) uracil and complex compounds based thereon, producing antineoplastic effect
JP2002255828A (ja) * 2001-02-28 2002-09-11 Ajinomoto Co Inc 抗腫瘍剤
TWI341728B (en) * 2002-01-14 2011-05-11 Novartis Ag Combinations comprising epothilones and anti-metabolites
DK1604991T3 (da) * 2003-03-14 2009-01-05 Taiho Pharmaceutical Co Ltd Antitumorvirkningsforstærker og antitumormiddel
PL1750703T3 (pl) * 2004-04-29 2012-05-31 Taiho Pharmaceutical Co Ltd Sposób obniżania toksyczności żołądkowo-jelitowej powodowanej podawaniem tegafuru
KR100844477B1 (ko) 2004-06-09 2008-07-07 다이호야쿠힌고교 가부시키가이샤 항종양 효과 증강제, 항종양제 및 암 치료 방법
ES2348996T3 (es) * 2005-04-01 2010-12-21 Taiho Pharmaceutical Co., Ltd. Potenciador de radioterapia.
JP4994618B2 (ja) * 2005-08-11 2012-08-08 学校法人北里研究所 Ｔｓ−１／カンプトテシン類による化学放射線療法
US8198264B2 (en) * 2006-04-28 2012-06-12 National Cancer Center Method for treating head and neck cancer
CN101921227B (zh) * 2007-04-03 2012-09-05 南京工业大学 5-氯-4-羟基-2(1h)-吡啶酮晶型及其制备方法和应用
TWI468188B (zh) 2008-01-30 2015-01-11 Univ Tokushima Anti-cancer effect enhancers consisting of oxaliplatin liposomal preparations and anticancer agents comprising the formulation
AU2008356312B2 (en) 2008-05-12 2015-04-09 Shizuoka Prefecture Antitumor agent, kit, and method for treating cancer
JPWO2010104035A1 (ja) 2009-03-12 2012-09-13 学校法人近畿大学 非小細胞肺癌に対する化学療法の治療効果予測方法
CN102369283A (zh) 2009-03-31 2012-03-07 德尔塔菲制药股份有限公司 靶向胸苷酸合酶的RNAi分子及其应用
TW201043237A (en) 2009-04-22 2010-12-16 Taiho Pharmaceutical Co Ltd Method for predicting a therapeutic effect of the chemotherapy for renal cell cancer
CA2761243A1 (en) 2009-05-12 2010-11-18 Taiho Pharmaceutical Co., Ltd. Anti-tumor agent containing tegafur-gimeracil-oteracil potassium combination drug and oxaliplatin
KR101441770B1 (ko) 2009-10-27 2014-09-17 데루타-후라이 화마 가부시키가이샤 신규 5-플루오로우라실 유도체
CN102309491B (zh) * 2010-07-02 2015-06-10 天津金耀集团有限公司 一种替加氟、吉美斯特复方注射液
US20140038966A1 (en) 2011-01-31 2014-02-06 Taiho Pharmaceutical Co., Ltd. Tegafur-containing composition for single daily and alternate-day dosing
ES2642170T3 (es) 2011-05-16 2017-11-15 Taiho Pharmaceutical Co., Ltd. Método para seleccionar la quimioterapia para un paciente con cáncer gástrico utilizando combinación de fármacos de tegafur, gimeracilo y oteracilo potásico e inhibidor de EGFR
EP2716290B1 (de) 2011-05-25 2018-03-14 Taiho Pharmaceutical Co., Ltd. Trockenbeschichtete tablette mit tegafur, gimeracil und oteracil-kalium
CN103159673B (zh) * 2011-12-12 2015-02-04 山东新时代药业有限公司 一种制备吉美嘧啶的精制方法
AU2013233094A1 (en) 2012-03-16 2014-10-23 Taiho Pharmaceutical Co., Ltd. Novel antitumor agent comprising combination of three agents
TW201400810A (zh) * 2012-06-01 2014-01-01 Taiho Pharmaceutical Co Ltd 對胃癌患者選擇化學療法之方法
CN114436822B (zh) * 2022-01-12 2024-04-16 厦门稀土材料研究所 一枝蒿酮酸和生物碱复盐及其制备方法和用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS55111420A (en) * 1979-02-20 1980-08-28 Ono Pharmaceut Co Ltd Antitumorigenic agent
JPS562913A (en) * 1979-06-21 1981-01-13 Ono Pharmaceut Co Ltd Antitumor agent
JPS5646867A (en) * 1979-09-25 1981-04-28 Ono Pharmaceut Co Ltd Pyridone derivative, its preparation and antineoplasmic agent
DK175432B1 (da) * 1984-10-30 2004-10-18 Otsuka Pharma Co Ltd Middel til forögelse af anticancervirkningen af anticancerforbindelser
JPS62155215A (ja) * 1984-11-30 1987-07-10 Otsuka Pharmaceut Co Ltd 抗腫瘍活性増強剤
WO1990007334A1 (en) * 1989-01-05 1990-07-12 Otsuka Pharmaceutical Co., Ltd. Non-injection carcinostatic agent for suppressing occurrence of inflammation due to 5-fluorouracil and method for curing cancer
JPH0578249A (ja) * 1991-09-20 1993-03-30 Taiho Yakuhin Kogyo Kk ５−フルオロウラシル類により起こる嘔気・嘔吐の防止及び治療剤

Also Published As

Publication number Publication date
DK0543015T3 (da) 1999-07-26
ES2124257T3 (es) 1999-02-01
TW209833B (de) 1993-07-21
AU1791292A (en) 1993-01-08
DE122011100040I2 (de) 2012-08-09
WO1992021345A1 (fr) 1992-12-10
HU211987A9 (en) 1996-01-29
EP0543015B1 (de) 1998-11-11
EP0543015A4 (en) 1994-06-01
ES2124257T4 (es) 2012-03-23
LU91852I2 (fr) 2011-10-03
CA2087540A1 (en) 1992-11-28
EP0543015A1 (de) 1993-05-26
DE69227571D1 (de) 1998-12-17
ATE173165T1 (de) 1998-11-15
JP2614164B2 (ja) 1997-05-28
AU654555B2 (en) 1994-11-10
US5525603A (en) 1996-06-11
KR0148589B1 (ko) 1998-11-02
CA2087540C (en) 1999-01-19
DE69227571T2 (de) 1999-04-29

Similar Documents

Publication Publication Date Title
DE122011100040I1 (de) Zusammensetzung, verfahren und instrument zur potenzierung der antitumoraktivitat und zur behandlungvon tumoren.
ATE396988T1 (de) Chinolin- und chianzolinderivate zur behandlung von tumoren
TW368501B (en) 7-(2-aminoethyl)-benzothiazolones
FI940414A (fi) Kinoliini- tai kinatsoliinijohdannaiset, niiden valmistus ja käyttö
DE69331171D1 (de) Chinolin und Chinazolin Derivate zur Behandlung von Arthritis
DE69406323D1 (de) Substituierte Aminsäure Derivate verwendbar für die Behandlung von Arteriosclerosis
ATE155469T1 (de) Verfahren zur herstellung von cephemderivaten
AU5795694A (en) New bicyclic nitrogen compounds, process for preparing them and pharmaceutical compositions containing them
ATE554094T1 (de) Verfahren zur herstellung von 3-cephem- verbindungen
ATE138376T1 (de) Verfahren zur herstellung von benzylphthalazinonderivaten und von deren salzen
DE69627519D1 (de) Sesquiterpen-derivate mit antiviraler aktivität
ATE84303T1 (de) Cysteinderivate.
FI842533A0 (fi) Hexahydropyrrolo/2,1-a/isokinolin- derivat.
ATE166654T1 (de) Verwendung von halogenierten beta-lactamen zur herstellung von 3-hydroxycephem-derivaten
DE69528984D1 (de) Hemmung der leukotrienbiosynthese mittels harnstoffderivaten
ATE200290T1 (de) Verfahren zur herstellung von indolocarbazol- derivaten
ATE88474T1 (de) Verfahren zur herstellung eines makrolidderivates.